• The primary objective of this Registry study is to evaluate the long-term safety of adalimumab in CD subjects who are treated as recommended in the local product label. [ Time Frame: Up to Five Years of Treatment ] [ Designated as safety issue: No ]
  

• The secondary objective is to evaluate long-term effectiveness of adalimumab in CD subjects who are treated as recommended in the local product label. [ Time Frame: Up to Five years of Treatment ] [ Designated as safety issue: No ]
  

As per the current approved Label

Inclusion Criteria:

• Subjects who are newly prescribed HUMIRA® (adalimumab) therapy (have never been treated with adalimumab) or who are participants in Abbott sponsored investigational CD trials, are currently receiving adalimumab and for whom the treating physician has made the decision to continue with adalimumab therapy beyond the duration of the investigational trial.
• Subjects who were participants in Abbott sponsored investigational Crohn's disease trials, who have not had dose interruptions since the last dose of study drug, where the Investigator can provide source documentation of serious adverse events, adverse events of interest and dosing information.
• Subjects who are currently receiving adalimumab, as per the local approved label, who have not had dose interruptions since the induction dose of adalimumab where the Investigator can provide source documentation of serious adverse events, adverse events of interest and dosing information.
• Subjects willing to consent to data being collected and provided to Abbott.
• Subjects capable of and willing to give written informed consent and to comply with the requirements of the Registry study protocol.

Exclusion Criteria:

• Subjects should not be enrolled if they cannot be treated in accordance with the local product label.